Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 15/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | CHKB | Q9Y259 | 1/20 | 0.63 |
| ▸ | KDM4A | O75164 | 1/20 | 0.55 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062537 | 0.92 | CHKA (1.00) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| Bromide SCHEMBL29616684 | 0.91 | CHKA (1.00) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL17190307 | 0.88 | CHKA (0.76) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL16378602 | 0.88 | CHKA (0.90) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL13851327 | 0.85 | CHKA (0.71) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1108048 | 0.84 | CHKA (1.00) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL580650 | 0.82 | CHKA (0.96) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1108058 | 0.82 | CHKA (1.00) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| Fluoride Ion SCHEMBL126024 | 0.81 | CHKA (0.93) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| Fluoride Ion SCHEMBL126023 | 0.81 | CHKA (0.93) | CHKAALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2015-04-09 | — | — | US | disclosed |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2015-04-09 | — | — | US | disclosed |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L (ES) | 2015-01-01 | — | — | US | disclosed |
| US-20120040021-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20110256241-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2011-10-20 | — | — | US | disclosed |
| US-20110250179-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2011-10-13 | — | — | US | disclosed |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256241-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, CHKA, ASAH2 | CHKA 2/4885ALDH1A1 1787/4885LMNA 2733/4885 |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CHKA, CHKB, CEPT1 | CHKA 1/4885ALDH1A1 2519/4885LMNA 3125/4885 |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | CHKA 4/4885ALDH1A1 1928/4885LMNA 2716/4885 |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | CHKA, CHKB, DCK | CHKA 1/4885ALDH1A1 2595/4885LMNA 4596/4885 |
| US-20110250179-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CHKA, CHKB, CEPT1 | CHKA 1/4885ALDH1A1 2519/4885LMNA 3125/4885 |
| US-20120040021-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | CHKA 4/4885ALDH1A1 1928/4885LMNA 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.